- Home
- WST vs BIIB Comparison
WST vs BIIB Comparison
Compare WST & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WST
- BIIB
- Stock Information
- Founded
- WST 1923
- BIIB 1978
- Country
- WST United States
- BIIB United States
- Employees
- WST N/A
- BIIB N/A
- Industry
- WST Medical/Dental Instruments
- BIIB Biotechnology: Pharmaceutical Preparations
- Sector
- WST Health Care
- BIIB Health Care
- Exchange
- WST Nasdaq
- BIIB Nasdaq
- Market Cap
- WST 23.2B
- BIIB 25.1B
- IPO Year
- WST N/A
- BIIB 1991
- Fundamental
- Price
- WST $332.77
- BIIB $149.02
- Analyst Decision
- WST Strong Buy
- BIIB Buy
- Analyst Count
- WST 5
- BIIB 26
- Target Price
- WST $437.75
- BIIB $248.00
- AVG Volume (30 Days)
- WST 494.1K
- BIIB 1.6M
- Earning Date
- WST 02-13-2025
- BIIB 02-11-2025
- Dividend Yield
- WST 0.25%
- BIIB N/A
- EPS Growth
- WST N/A
- BIIB 10.05
- EPS
- WST 6.74
- BIIB 11.06
- Revenue
- WST $2,876,400,000.00
- BIIB $9,607,500,000.00
- Revenue This Year
- WST N/A
- BIIB N/A
- Revenue Next Year
- WST $6.08
- BIIB N/A
- P/E Ratio
- WST $49.37
- BIIB $13.47
- Revenue Growth
- WST N/A
- BIIB N/A
- 52 Week Low
- WST $265.00
- BIIB $145.07
- 52 Week High
- WST $413.70
- BIIB $268.30
- Technical
- Relative Strength Index (RSI)
- WST 58.00
- BIIB 32.44
- Support Level
- WST $325.33
- BIIB $145.07
- Resistance Level
- WST $335.53
- BIIB $149.92
- Average True Range (ATR)
- WST 7.96
- BIIB 3.81
- MACD
- WST 0.32
- BIIB 0.05
- Stochastic Oscillator
- WST 78.28
- BIIB 22.51
About WST West Pharmaceutical Services Inc.
West Pharmaceutical Services is based in Pennsylvania, U.S., and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), non-glass containment solutions, and auto-injectors for injectable drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.